KB-1350

TNB383B-CD3-hIgG1

12289

Home » Antibodies » TNB383B-CD3-hIgG1

Background of TNB383B-CD3-hIgG1

TNB-383B is a laboratory-created antibody that facilitates the interaction between immune cells and cancer cells, resulting in a more targeted immune response. This antibody specifically targets the B-cell maturation antigen found in myeloma cells and the CD3 surface receptor present in T-cells, acting as a link between the two. The initial trial of TNB-383B in humans, conducted in collaboration with AbbVie, aims to assess the safety and tolerability of the compound, as well as various pharmacological characteristics including its peak concentration in the bloodstream and its half-life (the duration for a dose to decrease to half of its initial amount).

Specifications

Catalog Number	KB-1350
Antibody Name	TNB383B-CD3-hIgG1
Isotype	Human IgG1,kappa
Target	CD3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma